Table 4 Posteroanterior projected lung areas as measured using dynamic chest radiography

FitzMaurice et al. [30]

21

Contralateral (un-paralysed) side of diaphragm palsy cases

61 ± 13

172 ± 10

N/A

N/A

N/A

N/A

N/A

N/A

FitzMaurice et al. [29]

24

Cystic fibrosis (pre modulator drug treatment)

27 ± 6

167 ± 10

417 ± 81

334 ± 712

83 ± 40

0.69 (p < 0.001)

Cystic fibrosis (post modulator drug treatment)

28 ± 6

167 ± 10

416 ± 75

299 ± 72

117 ± 37

0.55 (p < 0.005)

FitzMaurice et al. [34]

20

Cystic fibrosis (during pulmonary exacerbation)

25 ± 7

164 ± 9

402 ± 67

321 ± 57

29 ± 14

0.69 (p < 0.001)

Cystic fibrosis (after treatment)

25 ± 7

164 ± 9

392 ± 61

303 ± 52

35 ± 10

N/A

Hino et al. [24]

162

Healthy volunteers

57 ± 10

163.4 ± 9

241 ± 30

201 ± 32

173 ± 30

141 ± 27

N/A

0.68 (p < 0.001)

Okhura et al. [25]

118

Airflow Limitation

71 ± 8

N/A

N/A

N/A

N/A

N/A

N/A

0.67 (p < 0.05)

Ohkura et al. [31]

273

All participants

N/A

N/A

N/A

N/A

N/A

N/A

N/A

0.5 (p < 0.05)

104

Normal spirometry

67 ± 10

162 ± 9

N/A

N/A

N/A

N/A

N/A

N/A

108

Mild airflow limitation (FEV₁ > 80% predicted)

72 ± 7

162 ± 9

N/A

N/A

N/A

N/A

N/A

N/A

25

Moderate airflow limitation (FEV₁ 50–80% predicted)

71 ± 4

163 ± 7

N/A

N/A

N/A

N/A

N/A

N/A

6

Severe airflow limitation (FEV₁ < 50% predicted)

64 ± 16

167 ± 8

N/A

N/A

N/A

N/A

N/A

N/A

14

Moderate restrictive disease (FVC 65–80% predicted)

70 ± 10

160 ± 10

N/A

N/A

N/A

N/A

N/A

N/A

16

Severe restrictive disease (FVC < 65% predicted)

60 ± 14

163 ± 8

N/A

N/A

N/A

N/A

N/A

N/A

Ueyama et al. [33]

97

Interstitial lung disease

73 (IQR: 66–77)

162 (IQR: 156–166)

N/A

N/A

N/A

N/A

N/A

0.73 (p < 0.001)